Exploratory analysis of the visceral disease (VD) patient subset in COU-AA-301, a phase III study of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC).

Authors

Oscar B. Goodman Jr.

Comprehensive Cancer Centers of Nevada, Las Vegas, NV

Oscar B. Goodman Jr., Thomas W. Flaig , Arturo Molina , Peter Mulders , Henrik Suttmann , Jinhui Li , Thian San Kheoh , Johann Sebastian De Bono , Howard I. Scher

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2014 Genitourinary Cancers Symposium

bookmark_border

Results from a phase 3, randomized, double-blind, multicenter, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based therapy (ELM-PC 5 trial).

First Author: Robert Dreicer

insert_chart_outlined

Poster

2015 ASCO Annual Meeting

bookmark_border

Phase 1b study of ARN-509 with abiraterone acetate (AA) and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

First Author: Edwin M. Posadas

insert_chart_outlined

Poster

2014 Genitourinary Cancers Symposium

bookmark_border

Association of alkaline phosphatase (ALP) with clinical outcomes in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results from COU-AA-302.

First Author: Evan Y. Yu

insert_chart_outlined

Poster

2013 ASCO Annual Meeting

bookmark_border

Relationship of baseline PSA and degree of PSA decline to radiographic progression-free survival (rPFS) in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): Results from COU-AA-302.

First Author: Charles J. Ryan